Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Viola W Zhu

Showing results (11-20 of 50) with videos related to

Pageof 5
Sort By:
Translational Lung Cancer Research|January 25, 2021
How to select the best upfront therapy for metastatic disease? Focus on <i>ALK</i>-rearranged non-small cell lung cancer (NSCLC)Bing Xia, Misako Nagasaka, Viola W Zhu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 18, 2020
Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLCMisako Nagasaka, Viola W Zhu, Sun Min Lim, et al.
JTO Clinical and Research Reports|September 30, 2021
A Novel Sequentially Evolved <i>EML4-ALK</i> Variant 3 G1202R/S1206Y Double Mutation In <i>Cis</i> Confers Resistance to Lorlatinib: A Brief Report and Literature ReviewViola W Zhu, Misako Nagasaka, Russell Madison, et al.
Lung Cancer (Auckland, N.Z.)|December 7, 2018
Dramatic response to alectinib in a lung cancer patient with a novel <i>VKORC1L1-ALK</i> fusion and an acquired ALK T1151K mutationViola W Zhu, Alexa B Schrock, Thangavijayan Bosemani, et al.
Lung Cancer (Amsterdam, Netherlands)|July 6, 2017
Identification of a novel T1151K ALK mutation in a patient with ALK-rearranged NSCLC with prior exposure to crizotinib and ceritinibViola W Zhu, J Jean Cui, Maria Fernandez-Rocha, et al.
Lung Cancer (Auckland, N.Z.)|February 6, 2020
Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in <i>ALK</i>-Rearranged NSCLC: A Report of Two CasesViola W Zhu, Misako Nagasaka, Takafumi Kubota, et al.
Lung Cancer (Amsterdam, Netherlands)|May 29, 2021
Thromboembolism in ALK+ and ROS1+ NSCLC patients: A systematic review and meta-analysisViola W Zhu, Joseph J Zhao, Yanfei Gao, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 27, 2016
Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 SkippingSai-Hong Ignatius Ou, Lauren Young, Alexa B Schrock, et al.
Lung Cancer (Amsterdam, Netherlands)|October 1, 2018
Carving out another slice of the pie: Exceptional response to single agent imatinib in an asian female never-smoker with advanced NSCLC with a de-novo PDGFR-α N848 K mutationSamuel J Klempner, Kyle Gowen, Thomas K Lee, et al.
Lung Cancer (Amsterdam, Netherlands)|June 20, 2017
Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinibSai-Hong Ignatius Ou, Jean Cui, Alexa B Schrock, et al.
Pageof 5

Showing results (11-20 of 50) with videos related to

Sort By:
Pageof 5
Translational Lung Cancer Research|January 25, 2021
How to select the best upfront therapy for metastatic disease? Focus on <i>ALK</i>-rearranged non-small cell lung cancer (NSCLC)Bing Xia, Misako Nagasaka, Viola W Zhu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 18, 2020
Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLCMisako Nagasaka, Viola W Zhu, Sun Min Lim, et al.
JTO Clinical and Research Reports|September 30, 2021
A Novel Sequentially Evolved <i>EML4-ALK</i> Variant 3 G1202R/S1206Y Double Mutation In <i>Cis</i> Confers Resistance to Lorlatinib: A Brief Report and Literature ReviewViola W Zhu, Misako Nagasaka, Russell Madison, et al.
Lung Cancer (Auckland, N.Z.)|December 7, 2018
Dramatic response to alectinib in a lung cancer patient with a novel <i>VKORC1L1-ALK</i> fusion and an acquired ALK T1151K mutationViola W Zhu, Alexa B Schrock, Thangavijayan Bosemani, et al.
Lung Cancer (Amsterdam, Netherlands)|July 6, 2017
Identification of a novel T1151K ALK mutation in a patient with ALK-rearranged NSCLC with prior exposure to crizotinib and ceritinibViola W Zhu, J Jean Cui, Maria Fernandez-Rocha, et al.
Lung Cancer (Auckland, N.Z.)|February 6, 2020
Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in <i>ALK</i>-Rearranged NSCLC: A Report of Two CasesViola W Zhu, Misako Nagasaka, Takafumi Kubota, et al.
Lung Cancer (Amsterdam, Netherlands)|May 29, 2021
Thromboembolism in ALK+ and ROS1+ NSCLC patients: A systematic review and meta-analysisViola W Zhu, Joseph J Zhao, Yanfei Gao, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 27, 2016
Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 SkippingSai-Hong Ignatius Ou, Lauren Young, Alexa B Schrock, et al.
Lung Cancer (Amsterdam, Netherlands)|October 1, 2018
Carving out another slice of the pie: Exceptional response to single agent imatinib in an asian female never-smoker with advanced NSCLC with a de-novo PDGFR-α N848 K mutationSamuel J Klempner, Kyle Gowen, Thomas K Lee, et al.
Lung Cancer (Amsterdam, Netherlands)|June 20, 2017
Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinibSai-Hong Ignatius Ou, Jean Cui, Alexa B Schrock, et al.
Pageof 5